BOTHELL, Wash.--(BUSINESS WIRE)--Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that research related to its antibody-drug conjugate (ADC) and sugar engineered antibody (SEA) technologies were presented at the 101st Annual Meeting of the American Association for Cancer Research (AACR) being held in Washington, D.C. The presentations demonstrate the mechanism of action of SGN-75, an ADC, in preclinical models and describe a novel approach for efficient, large-scale screening of antibodies for potential use as therapeutic ADCs. In addition, the company highlighted its SEA technology, which is designed to enhance the effector function of therapeutic antibodies.
